← Back to Home

Reconnecting Broken Vascular Signaling: First Clustering Antibody for HHT Enters Human Trials

DIAG723 does not make stopping bleeding its endpoint, but instead attempts to restore ALK1 signaling weakened by genetic variants. The first participant has been dosed, but testing has only just begun on whether this disease-modifying concept can clear the hurdles of early safety and efficacy in humans.

By SURL BioNews

For patients with hereditary hemorrhagic telangiectasia (HHT), the challenge is not merely occasional nosebleeds, but a biological mechanism that has been out of balance since blood vessel formation began. Fragile blood vessels can cause recurrent bleeding and chronic anemia, while arteriovenous malformations may also form in the lungs, liver, or brain. Now, the first patient has received DIAG723 in the Phase 1/2 DIAMOND trial, formally bringing into human testing a strategy that seeks to repair disease-causing signaling rather than merely address the consequences of bleeding.

DIAG723 is a subcutaneously administered “clustering agonist antibody.” It targets the ALK1 signaling pathway and is designed to bring receptors on the cell surface closer together, reactivating signaling weakened by loss-of-function genetic variants. This runs counter to the approach of many antibodies used to block overactive signaling: DIAG723 is intended not to turn the switch off, but to restore the function of a faulty switch.

The company said DIAG723 prevented and reversed arteriovenous malformations and also improved anemia in preclinical models of HHT; these results form the primary basis for its “disease-modifying” concept. However, the evidence currently remains limited to preclinical studies. It cannot yet be inferred that vascular lesions will regress in humans, nor does it establish that patients’ bleeding, transfusion requirements, or organ complications will necessarily improve.

The official trial registry shows that DIAMOND is a multicenter, randomized, double-blind, placebo-controlled study expected to enroll up to 93 adults. Part 1 uses single ascending doses to examine safety, tolerability, pharmacokinetics, and measures of target engagement in the ALK1 pathway. Part 2 involves multiple ascending doses over 14 weeks and will preliminarily assess nosebleed frequency and severity, as well as hematologic values. Part 3 will enroll patients with both HHT and pulmonary arterial hypertension to explore the effects of multiple doses on measures of both diseases.

The patient organization Cure HHT confirmed that the first patient has been dosed and noted that trial centers in Australia and New Zealand are recruiting, with additional international sites expected to join progressively. The organization is the patient advocacy partner for the study; its statement therefore adds information on recruitment progress and patient-side participation, but does not constitute independent validation of efficacy.

There is currently no treatment specifically approved for HHT that directly corrects its disease-causing mechanism. Clinical care largely focuses on controlling bleeding, providing iron supplementation, and managing anemia and arteriovenous malformations. At this stage, the most important questions for DIAMOND remain whether DIAG723 can safely restore the intended signaling in humans and whether changes in biomarkers can subsequently translate into meaningful clinical improvement. The trial is limited in size and its design includes several distinct populations and dosing stages; any early efficacy signal will need to be confirmed in larger studies with longer follow-up.

References

  1. ClinicalTrials.gov
  2. Cure HHT
  3. Pharma Now